Cargando…
Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
There have been significant improvements in therapeutic options for relapsed multiple myeloma (MM) over the past two decades, with many novel agents including proteasome inhibitors, immunomodulatory agents, and more recently monoclonal antibodies demonstrating efficacy in this setting. However, ther...
Autores principales: | Sterrett, Russell, Figueiredo, Amarilis, Mallick, Ranjeeta, Kekre, Natasha, Atkins, Harold, McCurdy, Arleigh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573024/ https://www.ncbi.nlm.nih.gov/pubmed/32967806 http://dx.doi.org/10.1016/j.htct.2020.07.007 |
Ejemplares similares
-
The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience
por: Figueiredo, Amarilis, et al.
Publicado: (2019) -
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017) -
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022) -
Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation
por: Felici, S, et al.
Publicado: (2013) -
Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)